ftInvstr
GRANULES · Healthcare ₹849.8 -0.84% Mkt Cap ₹21044 Cr

GRANULES

Healthcare Drug Manufacturers - Specialty & Generic
₹849.8
-0.84% today · 30d +1.14%
as of 2026-09-04
Price · Daily Candles
“Granules India surges 48% on strong earnings, as FIIs return despite a dip from DIIs.”
Granules India's stock has seen a 48.66% return over the past year, reaching near its 52-week high of ₹778.75. This performance is underpinned by robust Q4 2026 results, with revenue up 22.81% YoY to ₹1,471 Cr and net profit increasing by 32.58% YoY to ₹202 Cr. However, ML predictions indicate a weak outlook for Free Cash Flow (FCF) growth, while EBIT and Sales growth ranks remain strong.
BULL CASE
+Annual revenue growth of 19.73% and net profit growth of 18.64% for FY26, reaching ₹5,366 Cr and ₹595 Cr respectively.
+Q4 2026 revenue increased by 22.81% YoY to ₹1,471 Cr, with net profit up 32.58% YoY to ₹202 Cr.
+Operating profit margin (OPM) saw a 3.19% YoY increase in Q4 2026, reaching 24.39%.
+FII shareholding increased by 1.52 percentage points QoQ to 15.31% as of March 2026.
+The stock is trading near its 52-week high, only -2.79% below ₹778.75, showing strong price momentum.
BEAR CASE
ML predictions for Free Cash Flow (FCF) growth are weak, with a rank of 0.0 for 4-year rolling and 0.032 for 7-year stable FCF.
DII shareholding decreased by 1.5 percentage points QoQ to 17.01% as of March 2026.
The 5-year CAGR for net profit is a modest 1.61%, despite higher revenue growth.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹1471 Cr
+22.81% YoY
NET PROFIT
₹202 Cr
+32.58% YoY
OPM
24.39%
+3.19pp YoY
EPS
₹8.23
PE 30.88
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-27.1%, h2=-23.5%, h3=-22.5% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Granules India, with a TTM PE of 30.88 and ROCE of 15.0%, trades at a lower valuation but also trails in profitability compared to sector leaders like Sun Pharma (PE 40.41, ROCE 22.46%) and Dr. Reddy's (PE 19.55, ROCE 27.63%).
PEERPEROCE %
GRANULES30.8815.0
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
69
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation FAIR 40
Growth STRONG 73
Profitability HIGH 78
Technicals NEUTRAL 52
Risk LOW 70
Key Stats
TTM PE
30.88
P/B
3.64
52W HIGH
₹910.0
OFF HIGH
-6.62%
DIV YIELD
0.23%
MKT CAP
₹21044 Cr
◉ Active Signals
MACDBearish-0.1119
RSI(14)Neutral52.11
Street Consensus
7 analysts
₹772.14
mean target
Low ₹588.0Now ₹849.8High ₹856.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold GRANULES and at what entry.

Sign up freeSign in